Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Sequencing 412 Japanese and Italian biliary cancers, including 66 gallbladder and cystic duct tumours, found 32 driver genes and, unexpectedly, an inherited cancer-predisposing mutation in about one in nine patients.
Overview
412 biliary tract cancer samples from Japanese and Italian populations were analysed, 107 by whole-exome sequencing, 39 by whole-genome sequencing and 266 by targeted sequencing: 136 intrahepatic, 101 distal and 109 perihilar cholangiocarcinomas and 66 gallbladder or cystic duct cancers. Thirty-two significantly and commonly mutated genes were identified, including TP53, KRAS, SMAD4, NF1, ARID1A, PBRM1 and ATR, some of which negatively affected prognosis, and a novel deletion of MUC17 at 7q22.1 affected prognosis.
Cell-of-origin predictions using whole-genome and epigenetic features suggested a hepatocyte origin for hepatitis-related intrahepatic cholangiocarcinoma. Deleterious germline mutations of cancer-predisposing genes such as BRCA1, BRCA2, RAD51D, MLH1 or MSH2 were detected in 11% (16 of 146) of patients.
- 32 significantly mutated genes including TP53, KRAS, SMAD4, NF1, ARID1A, PBRM1 and ATR.
- Deleterious germline variants in BRCA1, BRCA2, RAD51D, MLH1 or MSH2 in 11% (16 of 146) of patients.
- A MUC17 deletion at 7q22.1 affected prognosis.
The germline finding is the practical lesson: a meaningful minority of biliary cancer patients carry inherited repair-gene mutations that matter for PARP inhibitor eligibility and for their relatives, which argues for germline testing alongside tumour sequencing.
- Gallbladder cancers were 66 of 412 and not always reported separately.
- Germline analysis covered 146 of the patients.
Similar pages
not linked directly; found by shared links- TreatmentVENTANA MMR RxDx Panel
Shares MSH2, MLH1, dMMR (mismatch repair deficiency by IHC), Lynch syndrome.
- Key paperBiliary cancer: utility of next-generation sequencing for clinical management
Shares ARID1A, SMAD4, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
- Key paperMolecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Shares Homologous recombination deficiency (HRD), BRCA1 / BRCA2 (HRD), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
- Key paperRegional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations
Shares ARID1A, SMAD4, Gallbladder cancer.
- Key paperMolecular and clinical determinants of targeted therapy treatment in biliary tract cancer
Shares SMAD4, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
- TrialOlanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
Shares Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
- TrialCandonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
Shares Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
- TrialTripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Shares Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.